MX2021006011A - Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. - Google Patents

Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.

Info

Publication number
MX2021006011A
MX2021006011A MX2021006011A MX2021006011A MX2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A MX 2021006011 A MX2021006011 A MX 2021006011A
Authority
MX
Mexico
Prior art keywords
aurora
neuroblastoma
treatment
kinase inhibitor
kinase
Prior art date
Application number
MX2021006011A
Other languages
English (en)
Inventor
Louis Frank Stancato
Michele Suzanne Dowless
Xueqian Gong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021006011A publication Critical patent/MX2021006011A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un inhibidor de la quinasa Aurora A que se ilustra a continuación, (ver Fórmula) o una sal aceptable desde el punto de vista farmacéutico de este, para su uso en el tratamiento del neuroblastoma.
MX2021006011A 2018-11-30 2019-11-22 Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. MX2021006011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773367P 2018-11-30 2018-11-30
PCT/US2019/062718 WO2020112514A1 (en) 2018-11-30 2019-11-22 An aurora a kinase inhibitor for use in the treatment of neuroblastoma

Publications (1)

Publication Number Publication Date
MX2021006011A true MX2021006011A (es) 2021-09-21

Family

ID=68916597

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006011A MX2021006011A (es) 2018-11-30 2019-11-22 Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.

Country Status (15)

Country Link
US (1) US20220000855A1 (es)
EP (1) EP3886855A1 (es)
JP (2) JP2022508183A (es)
KR (1) KR20210084555A (es)
CN (1) CN113038950A (es)
AU (1) AU2019388843B2 (es)
BR (1) BR112021006578A2 (es)
CA (1) CA3121483A1 (es)
EA (1) EA202191051A1 (es)
IL (1) IL282270A (es)
MA (1) MA54290A (es)
MX (1) MX2021006011A (es)
SG (1) SG11202104344RA (es)
UA (1) UA125892C2 (es)
WO (1) WO2020112514A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
CN117836285A (zh) * 2021-07-28 2024-04-05 北京加科思新药研发有限公司 Aurora a选择性抑制剂的多晶型及其用途
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9576309B2 (en) 2014-11-12 2017-02-21 Snergy Inc. Dynamic power sharing system and map view graphical user interface
TWI693218B (zh) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑

Also Published As

Publication number Publication date
EA202191051A1 (ru) 2021-08-26
AU2019388843B2 (en) 2023-03-23
UA125892C2 (uk) 2022-06-29
KR20210084555A (ko) 2021-07-07
WO2020112514A1 (en) 2020-06-04
CN113038950A (zh) 2021-06-25
CA3121483A1 (en) 2020-06-04
MA54290A (fr) 2022-03-09
JP2023058582A (ja) 2023-04-25
JP2022508183A (ja) 2022-01-19
BR112021006578A2 (pt) 2021-07-27
SG11202104344RA (en) 2021-05-28
AU2019388843A1 (en) 2021-05-20
EP3886855A1 (en) 2021-10-06
US20220000855A1 (en) 2022-01-06
IL282270A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
ZA202202097B (en) Amino pyrimidine ssao inhibitors
MX2017013797A (es) Inhibidor de janus quinasa.
SA519401541B1 (ar) [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات
NZ763551A (en) Compounds useful for inhibiting cdk7
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
EA202193015A1 (ru) Ингибиторы cdk
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
NZ730771A (en) Aurora a kinase inhibitor
TN2019000211A1 (en) Antitumoral compounds
MX2022007626A (es) Combinaciones.
MX2019006079A (es) Derivados de oxoisoquinolina novedosos.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
MX2022007623A (es) Combinaciones.
MX2022007625A (es) Combinaciones.
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.